Category: 記事

The market access function is an important one, but based on my experience, it is often misunderstood and the timing of when it should be added to the corporate leadership team.. (cont.)

For some time now, cancer drug developers have known “Project Optimus” and new dose optimization expectations are coming their way from the Food and Drug Administration’s (FDA) Oncology Center of Excellence for Oncology Drugs… By Julie Bullock, PharmD

Using data visualizations to improve access to payers. With the switch to more digital environments, ever increasing budgetary constraints, and emphasis on value-based healthcare… (cont.)

Is there a better way? The question always breeds critical thinking and often leads to new solutions. In this discussion, it can entirely rewrite the approach to, and relieve many of, the common pitfalls experienced during…

“Quantitative decision-making with data rather than empirical thinking” – Certara’s Modeling & Simulation technology contributes to accelerate new drug development Certara G.K. held an online press seminar on 2022年8月31日 (水曜日), in Tokyo, on the optimization of the drug development process and the role of a drug discovery consulting company. In Japan, local demand … Continued

Today, we are interviewing Professor Gyujeong Noh from Anesthesiology and Pain Medicine/Clinical Pharmacology and Therapeutics at University of Ulsan College of Medicine, Asan Medical Center, South Korea to shed a light on his experience as a clinician on how to apply pharmacokinetic and pharmacodynamic analysis to clinical research and practice. Professor Noh adopts a unique … Continued

We have often seen Dr. Hwi-yeol (Thomas) Yun, Associate Professor/Adjunct Professor at the College of Pharmacy and Bio-AI Convergence Research Center of Chungnam National University, listed as a guest presenter at key Pharmacometrics conferences across the Asia-Pacific region, as well as at local Korean events. In 2020, he also presented to a large audience at … Continued

Certara’s Phoenix biosimulation software platform is widely used for non-compartmental analysis (NCA), pharmacokinetic/pharmacodynamic (PK/PD), and population PK analysis. Recently, we have seen how Certara software helps customers accelerate collaboration across their divisions and groups for better clinical results. Today, we interviewed Sun Hua, Associate Chief Pharmacist at Yijishan Hospital, Drug Evaluation Center, Wannan Medical College, … Continued